Clinical trials: Colorectal Carcinoma (CRC)
Colorectal Cancer
The Impact of Covid-19 Pandemic on Colorectal Cancer Prevention Due to Delays in Diagnosis: a Global Study
Screening programs have been associated with a substantial reduction in colorectal cancer (CRC) mortality through endoscopic resection of preneoplastic lesions and detection of early-stage invasive cancers.
- Trial name
- COVID_CRC (NCT04637893)
- Testing
- Colonoscopy
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Istituto Clinico Humanitas
Colorectal Cancer
Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
This study is for people with colorectal cancer, who have tumors that cannot be completely removed by surgery. This study is being done to find out how long it takes tumors to grow after patients receive the drugs capecitabine…
- Trial name
- NCT00159432
- Testing
- Oxaliplatin, Bevacizumab, Capecitabine
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Southern California
Colorectal Cancer
A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)
This is an open-label, single center, non-randomized, phase Ⅱ trial to evaluate safety and efficacy of using the combination treatment of Camrelizumab with anti-angiogenic drugs and Chemotherapy of metastatic colorectal mucinous…
- Trial name
- NCT04446091
- Testing
- Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.), Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Colorectal Cancer
Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Patients with metastatic colorectal cancer will be treated with chemotherapy according to investigators choice. In addition to chemotherapy treatment, treatment with bevacizumab will be given concomitantly.
- Trial name
- ACT2 (NCT01229813)
- Testing
- bevacizumab, erlotinib, bevacizumab, low dose capecitabine
- Where
- 12 sites in Denmark, Sweden
- Volunteers
- 233 people
- Sponsor
- Lund University Hospital
Colorectal Cancer, Mortality
Dietary Patterns, Metabolomics and Colorectal Cancer Risk
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in American men and women with ≥130,000 new cases each year.
- Trial name
- NCT03364582
- Testing
- Observed dietary pattern
- Volunteers
- 173,230 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Colorectal Cancer
Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00628810
- Testing
- bevacizumab, fluorouracil, irinotecan hydrochloride
- Where
- 32 sites in France
- Volunteers
- 86 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Colorectal Cancer, Metastases
Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
This is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal cancer. The objectives of the study are to obtain information on the safety of radiolabeled IDEC-159, as well as its activity in…
- Trial name
- NCT00102024
- Testing
- Unconjugated IDEC-159, 111In-IDEC-159, 90Y-IDEC-159
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Biogen
Solid Tumor Cancer, Solid Tumor, Unspecified, Adult
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.
- Conditions
- Solid Tumor Cancer, Solid Tumor, Unspecified, Adult, Colorectal Carcinoma, Colorectal Carcinoma (CRC)
- Trial name
- DESCENT-1 (NCT06885424)
- Testing
- No additional intervention administered in this long term follow-up study
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- A2 Biotherapeutics Inc.
Colorectal Cancer Liver Metastases (CRLM), Metastatic Colorectal Carcinoma (mCRC)
Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases
Colorectal cancer is the third most common malignancy worldwide, and prognosis largely depends on how effectively metastatic disease is managed.
- Trial name
- EXELION (NCT07224724)
- Testing
- EXELION
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer
ctDNA as a Prognostic Marker for Postoperative Relapse in Early and Intermediate Stage Colorectal Cancer
By monitoring the serum ctDNA mutational profile using NGS, the present clinical trial aims to elucidate the correlation between the postoperative ctDNA status and the prognosis of patients with early and intermediate-stage…
- Trial name
- NCT03312374
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Sun Yat-sen University
Laparoscopy
Outcome of Resection for Colorectal Cancer
There are limited data from retrospective studies regarding whether short-term and long-term outcomes after laparoscopic or robot-assisted radical colectomy (minimally invasive surgery) are equivalent to those after open…
- Trial name
- LRLCC (NCT03837782)
- Testing
- minimally invasive surgery
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Bladder Cancer, Colorectal Cancer
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
The goal of this study is to understand factors which may influence risk for colorectal and other cancers in families. These factors include genetic variability, in combination with diet and lifestyle.
- Conditions
- Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer
- Trial name
- NCT01447199
- Testing
- Health and Diet Questionnaire
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors.
- Trial name
- DPT02 (NCT04482309)
- Testing
- Trastuzumab deruxtecan
- Where
- 89 sites in United States, Australia and 15 more
- Volunteers
- 477 people
- Sponsor
- AstraZeneca
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
- Trial name
- innovaTV 207 (NCT03485209)
- Testing
- tisotumab vedotin, pembrolizumab, carboplatin
- Where
- 175 sites in United States, Canada and 5 more
- Volunteers
- 350 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Colorectal Cancer, Pancreatic Adenocarcinoma
Circulating Tumor DNA Exposure in Peripheral Blood
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the…
- Conditions
- Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT03517332
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Quantgene Inc.
Colorectal Cancer
Changes in Stem Cells of the Colon in Response to Increased Risk of Colorectal Cancer
Colorectal cancer is a common disease worldwide. Increasing evidence is demonstrating that colorectal cancers arise from 'cancer stem cells.' Stem cells in the colon reside at the bottom of thousands of microscopic crypts…
- Trial name
- NCT01075893
- Where
- 2 sites in United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Newcastle University
Metastatic Colorectal Cancer
RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO)
Some data have suggested a clinical survival benefit related to the reintroduction of anti-EGFRs therapy in patients with metastatic colorectal cancer (mCRC).
- Trial name
- RASINTRO (NCT03259009)
- Volunteers
- 73 people
- Sponsor
- Association des Gastroentérologues Oncologues
Rectal Cancer (Stage III)
Diagnostic Accuracy and Prognostic Value of 18F FDG PET-CT in the Follow up of Patients With Colorectal Carcinoma.
The goal of this observational study is to learn about the diagnostic and prognostic value of 18f fdg pet ct in follow up of colorectal cancer patients The main question it aims to answer is: Does pet ct have a role in treatment…
- Trial name
- NCT07536321
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.